Table 3.
Device and Pharmacologic Approach to Therapy of the Brugada Syndrome
| Devices and Ablation |
| ICD 199 |
| Radiofrequency Ablation 83, 208–212 |
| ? Pacemaker 204–206 |
| Pharmacologic Approach to Therapy |
| Ineffective or Proarrhythmic |
| Amiodarone 282 |
| β Blockers 282 |
| Class IC antiarrhythmics |
| Flecainide 38 |
| Propafenone 267 |
| ? Disopyramide 214 |
| Class IA antiarrhythmics |
| Procainamide37 |
| Effective for Treatment of Electrical Storms |
| β Adrenergic agonists – isoproterenol 46, 51, denopamine230, orciprenaline 226, 236 |
| Phosphodiesterase III Inhibitors-cilostazol 235 |
| Effective General Therapy |
| Quinidine 168, 218–220, 231–233 |
| Bepridil - Ito-inhibition and INa augmentation258 |
| Cilostazol combined with bepridil 251 |
| Experimental Therapy |
| Ito Blockers - cardioselective and ion channel specific |
| Quinidine 168 |
| 4-aminopyridine 168 |
| Tedisamil 283 |
| AVE0118 284 |
| PDE-3-inhibitors |
| Cilostazol – Increase in ICa and inhibition of Ito 253, 285 |
| Milrinone - ICa augmentation 253, 285 |
| Traditional Chinese Medicine |
| Dimethyl lithospermate B – Increase in INa due to slowed inactivation |
| Wenxin Keli - combined Ito-block and tyramine-like effect216 |